Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.

Clinical pharmacology and therapeutics - 1 Jun 2016

Matthaei J, Kuron D, Faltraco F, Knoch T, Dos Santos Pereira J N, Abu Abed M, Prukop T, Brockmöller J, Tzvetkov M V

Abstract excerpt

The low bioavailability of the anti-migraine drug sumatriptan is partially caused by first-pass hepatic metabolism. In this study, we analyzed the impact of the hepatic organic cation transporter OCT1 on sumatriptan cellular uptake, and of OCT1 polymorphisms on sumatriptan pharmacokinetics. OCT1 transported sumatriptan with high capacity and sumatriptan uptake into human hepatocytes was strongly inhibited by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability
Share to Cell Membrane Permeability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to HEK293 Cells

Share to Hepatocytes

Share to Migraine Disorders

Share to Octamer Transcription Factor-1

Share to Serotonin Receptor Agonists

Source

Identifiers

PMID: 26659468
DOI: 10.1002/cpt.317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.PMID 26659468Read ↗

OCT1 pharmacogenetics in pain management: is a clinical application within reach?Semantic proximity Read ↗

Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.Semantic proximity Read ↗

Genetic variation in organic cation transporters and considerations in drug development.Semantic proximity Read ↗

The human organic cation transporter OCT1 and its role as a target for drug responsesSemantic proximity Read ↗

Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.Semantic proximity Read ↗

Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans.Semantic proximity Read ↗

Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.Semantic proximity Read ↗

Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interactionSemantic proximity Read ↗

Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.Semantic proximity Read ↗

Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulationSemantic proximity Read ↗

Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.Semantic proximity Read ↗

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.